Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-07
2011-06-07
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S374000, C548S215000, C544S139000
Reexamination Certificate
active
07956055
ABSTRACT:
A compound having the formulaor a pharmaceutically acceptable salt or a prodrug thereof is disclosed herein. Y, A, U, and B are as described herein.Methods, compositions, and medicaments related to these compounds are also disclosed.
REFERENCES:
patent: 4166452 (1979-09-01), Generales
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen
patent: 5462968 (1995-10-01), Woodward
patent: 5698598 (1997-12-01), Woodward
patent: 5902726 (1999-05-01), Kliewer
patent: 6090847 (2000-07-01), Woodward
patent: 6437146 (2002-08-01), Hattori
patent: 6573294 (2003-06-01), Old
patent: 6710072 (2004-03-01), Burk
patent: 7091231 (2006-08-01), Donde
patent: 7553860 (2009-06-01), Old
patent: 2007/0203222 (2007-08-01), Old
patent: 1 481 976 (2004-12-01), None
patent: WO 2004/019938 (2004-03-01), None
patent: WO 2004/037808 (2004-05-01), None
patent: WO 2006/098918 (2006-09-01), None
patent: WO2007/109575 (2007-09-01), None
U.S. Appl. No. 12/471,000, filed May 22, 2009, Old.
U.S. Appl. No. 60/660,740, filed Mar. 10, 2005, Chen.
U.S. Appl. No. 60/777,506, filed Feb. 28, 2006, Old.
Baxter, Anthony D., et al., “Synthesis and Use of 7-Substituted Norbornadienes + for the Preparation of Prostaglandins and Prostanoids,” J. Chem. Soc. Perkin Trans. I, 1986, pp. 889-900.
Chourasia, M.K. ;Jain, S.K.: Pharmaceutical Approaches to Colon Targeted Drug Delivery Systems. J Pharm Pharmaceut Sci 6 (1): 33-66, 2003.
Ding et al., An Efficient Synthesis of Optically Pure (S)-2-Functionalized 1,2,3,4-Tetrahedron Letters, 45, 1027-1029, 2004.
Dragoli, Dean R., et al., “Parallel Synthesis of Prostaglandin E1 Analogues,” J. Comb. Chem. 1999,I, pp. 534-539.
Kwon et al., Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism from Industrial Scientists, 2001, http://www.my.library.com/Browse/open.asp?ID=4284&loc=1, Retrieved from the Internet Jun. 16, 2008, p. 213.
Metabolomics [Online], Retrieved from the Internet Jun. 16, 2008, www.en.wikipedia.org/wiki/Metabolomics.
Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 16thEdition, 1980.
Saijo et al.: Heterocyclic Prostaglandins. VI. Synthesis of 11-Deoxy-8,10-Diazaprostaglandin E1 and its 10-Methyl Derivatice. Chem. Pharm. Bull. 1980, 28, 1459-1467.
Shareef, Ajmal; et al.: Colonic Drug Delivery: An Updated Review. AAPS PharmSci 2003; 5(2) Article 17.
Sibi, Mukund and Renhowe, Paul: A New Nucleophilic Alaninol Synthon From Serine. Tetrahedron Lett. 1990, 31, 7407-7410.
Wolff et al., Burger's Medicinal Chemistry and Drug Discovery, 1994, Wiley-Interscience, Fifth Edition, vol. 1: Principles and Practice, pp. 975-977.
Allergan Inc.
Anderson Rebecca L
Ene Doina G.
Forrestal Kevin J.
Wurst John E.
LandOfFree
Substituted gamma lactams as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted gamma lactams as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted gamma lactams as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650196